- Home
- IMNM
IMNM
Immunome Inc.
as 11-17-2025 3:44pm EST
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 1.2B | IPO Year: | 2020 |
| Target Price: | $25.75 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.15 - $18.79 | Next Earning Date: | 11-06-2025 |
| Revenue: | $9,679,000 | Revenue Growth: | -4.44% |
| Revenue Growth (this year): | -14.99% | Revenue Growth (next year): | 85.36% |
Latest Immunome Inc. News
IMNM Breaking Stock News: Dive into IMNM Ticker-Specific Updates for Smart Investing
Business Wire
17 days ago
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference
MT Newswires
2 months ago
Goldman Sachs Initiates Immunome at Buy With $26 Price Target
MT Newswires
2 months ago
Craig-Hallum Initiates Immunome at Buy With $26 Price Target
Business Wire
2 months ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
5 months ago
Immunome (IMNM) Upgraded to Buy: Here's What You Should Know
Zacks
5 months ago
Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?
Business Wire
5 months ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
6 months ago
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet
Compare IMNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMNM Immunome Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.